Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-650 (Infliximab) in pediatric moderate to severe Crohn's disease
NCT01580670Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Mar 2012
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab in Crohn's disease, sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Percent of Patients Who Achieved Pediatric Crohn's Disease Activity Index Response at 54 weeks. Started Mar 2012; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01580670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01580670.